Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer
Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.
Related Articles
Fox Chase Cancer Center’s Dr. Richard J. Bleicher Appointed Vice Chair of the National Accreditation Program for Breast Centers and Chair of its Executive Committee
Richard J. Bleicher, MD, FACS, Chief of the Division of Breast Surgery and Clinical Director of the Breast Service Line at Fox Chase Cancer Center.
The AACR June L. Biedler Prize for Cancer Journalism
The AACR June L. Biedler Prize for Cancer Journalism is a program of the AACR to raise awareness of the critical role that the media…
Destination Healthy Skin Support
Help The Skin Cancer Foundation purchase and customize a new RV to keep our Destination Healthy Skin program on the road.
Schlechter named Cancer Moonshot Scholar
Chelsey Schlechter, MPH, PhD, has been chosen as a Cancer Moonshot Scholar. She is one of eleven researchers from across the country who have been…
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
Key PointsELN 2017 and 2022 prognostic classifiers did not adequately stratify OS outcomes for patients with AML treated with venetoclax-azacitidine.A 4-ge
Effectiveness of a Cardiovascular Health Electronic Health Record Application for Cancer Survivors in Community Oncology Practice: Results From WF-1804CD | Journal of Clinical Oncology
PURPOSEGuidelines recommend cardiovascular (CV) risk assessment and counseling for cancer survivors. This study evaluated the automated heart-health assessment (AH-HA) clinical decision support tool to promote…
Belantamab Mafodotin Combos Accepted for Review by FDA in Multiple Myeloma
A BLA has been accepted by the FDA for 2 belantamab mafodotin combinations that have shown positive results in patients with multiple myeloma.
Knowing your risk for inherited cancers matters
Testing for inherited cancer risk has become more accessible, affordable and accurate. Fred Hutch clinicians and researchers explain why it can be important, how to…
Health Canada Approves Cilta-Cel for Relapsed/Lenalidomide-Refractory Myeloma
Health Canada has approved cilta-cel for use in patients with relapsed/lenalidomide-refractory multiple myeloma following 1 to 3 prior lines of therapy.
CVAD Blood Specimen Collection: Mixing Method Noninferior to Discard Method – Oncology Nurse Advisor
A quasi-experimental study sought to compare the 2 blood specimen collection methods to determine if one performed better for patients with central venous access devices.
